Orbimed Advisors LLC sold $39M of ELVN
owner at Enliven Therapeutics, Inc.. 860,123 shares at an average of $45.36, traded Jun 22, 2026, filed Jun 24, 2026.
Score components
- +12Role10% owner
- +25Trade size$39.0M at market
- +20Share of holdings soldSold 100% of holdings
- +15Cluster4 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000947871-26-000653, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jun 22, 2026 | SOpen-market sale Common Stockindirect: See Footnotes | -24,846 | $45.38 | $1.1M | 220,882 | Jun 24, 2026 |
| Jun 22, 2026 | SOpen-market sale Common Stockindirect: See Footnotes | -1,477 | $45.00 | $66k | 219,405 | Jun 24, 2026 |
| Jun 22, 2026 | SOpen-market sale Common Stockindirect: See Footnotes | -787,024 | $45.38 | $36M | 6,601,878 | Jun 24, 2026 |
| Jun 22, 2026 | SOpen-market sale Common Stockindirect: See Footnotes | -46,776 | $45.00 | $2.1M | 6,555,102 | Jun 24, 2026 |
Related signals
Other insiders at Enliven Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 54Moderate | Enliven Therapeutics, Inc. | J. Scott Garland director | $607k 13,000 shares | -100% | |
| 13Weak | Enliven Therapeutics, Inc. | Helen Louise Collins CHIEF MEDICAL OFFICER | $252k 5,000 shares | -17% | |
| 21Weak | Enliven Therapeutics, Inc. | Benjamin Hohl CHIEF FINANCIAL OFFICER | $303k 6,018 shares | -14% | |
| 14Weak | Enliven Therapeutics, Inc. | Helen Louise Collins CHIEF MEDICAL OFFICER | $293k 5,000 shares | -17% | |
| 37Weak | Enliven Therapeutics, Inc. | Benjamin Hohl CHIEF FINANCIAL OFFICER | $353k 6,018 shares | -13% | |
| 40Moderate | Enliven Therapeutics, Inc. | Mika K Derynck director | $9.6M 158,795 shares | -100% | |
| 13Weak | Enliven Therapeutics, Inc. | Helen Louise Collins CHIEF MEDICAL OFFICER | $263k 5,000 shares | -17% | |
| 21Weak | Enliven Therapeutics, Inc. | Benjamin Hohl CHIEF FINANCIAL OFFICER | $317k 6,018 shares | -12% | |
| 33Weak | Enliven Therapeutics, Inc. | Lori Anne Kunkel director | $505k 10,000 shares | -19% | |
| 12Weak | Enliven Therapeutics, Inc. | Helen Louise Collins CHIEF MEDICAL OFFICER | $219k 5,000 shares | -17% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.